Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chang Ik Choi

Showing results (51-60 of 69) with videos related to

Pageof 7
Sort By:
Archives of Pharmacal Research|January 6, 2025
Physiologically based pharmacokinetic (PBPK) modeling of gliclazide for different genotypes of CYP2C9 and CYP2C19Hye-Jung Park, Sang-Ho Lee, Pureum Kang, et al.
Archives of Pharmacal Research|November 24, 2021
Physiologically based pharmacokinetic modeling of candesartan related to CYP2C9 genetic polymorphism in adult and pediatric patientsEui Hyun Jung, Chang-Keun Cho, Pureum Kang, et al.
Archives of Pharmacal Research|December 21, 2022
Effects of CYP2D6*10 allele on the pharmacokinetics of tolperisoneChang-Keun Cho, Ji-Young Byeon, Pureum Kang, et al.
Archives of Pharmacal Research|July 6, 2016
Effects of CYP2C9 genetic polymorphisms on the pharmacokinetics of zafirlukastHyun-Jee Lee, Young-Hoon Kim, Se-Hyung Kim, et al.
Archives of Pharmacal Research|November 22, 2017
Inhibition of salivary secretion by tolterodine transdermal patchJi-Yeong Byeon, Young-Hoon Kim, Se-Hyung Kim, et al.
European Journal of Clinical Pharmacology|July 25, 2018
Effects of CYP2C19 and CYP3A5 genetic polymorphisms on the pharmacokinetics of cilostazol and its active metabolitesHye-In Lee, Ji-Young Byeon, Young-Hoon Kim, et al.
Archives of Pharmacal Research|May 6, 2018
Effects of diltiazem, a moderate inhibitor of CYP3A4, on the pharmacokinetics of tamsulosin in different CYP2D6 genotypesJi-Yeong Byeon, Yun Jeong Lee, Young-Hoon Kim, et al.
Archives of Pharmacal Research|June 28, 2022
Physiologically based pharmacokinetic modelling to predict the pharmacokinetics of metoprolol in different CYP2D6 genotypesChoong-Min Lee, Pureum Kang, Chang-Keun Cho, et al.
Archives of Pharmacal Research|February 26, 2015
Effects of CYP2C9*1/*3 genotype on the pharmacokinetics of flurbiprofen in Korean subjectsYun-Jeong Lee, Ji-Yeong Byeon, Young-Hoon Kim, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|September 30, 2014
Simultaneous determination of flurbiprofen and its hydroxy metabolite in human plasma by liquid chromatography-tandem mass spectrometry for clinical applicationHye-In Lee, Chang-Ik Choi, Ji-Yeong Byeon, et al.
Pageof 7

Showing results (51-60 of 69) with videos related to

Sort By:
Pageof 7
Archives of Pharmacal Research|January 6, 2025
Physiologically based pharmacokinetic (PBPK) modeling of gliclazide for different genotypes of CYP2C9 and CYP2C19Hye-Jung Park, Sang-Ho Lee, Pureum Kang, et al.
Archives of Pharmacal Research|November 24, 2021
Physiologically based pharmacokinetic modeling of candesartan related to CYP2C9 genetic polymorphism in adult and pediatric patientsEui Hyun Jung, Chang-Keun Cho, Pureum Kang, et al.
Archives of Pharmacal Research|December 21, 2022
Effects of CYP2D6*10 allele on the pharmacokinetics of tolperisoneChang-Keun Cho, Ji-Young Byeon, Pureum Kang, et al.
Archives of Pharmacal Research|July 6, 2016
Effects of CYP2C9 genetic polymorphisms on the pharmacokinetics of zafirlukastHyun-Jee Lee, Young-Hoon Kim, Se-Hyung Kim, et al.
Archives of Pharmacal Research|November 22, 2017
Inhibition of salivary secretion by tolterodine transdermal patchJi-Yeong Byeon, Young-Hoon Kim, Se-Hyung Kim, et al.
European Journal of Clinical Pharmacology|July 25, 2018
Effects of CYP2C19 and CYP3A5 genetic polymorphisms on the pharmacokinetics of cilostazol and its active metabolitesHye-In Lee, Ji-Young Byeon, Young-Hoon Kim, et al.
Archives of Pharmacal Research|May 6, 2018
Effects of diltiazem, a moderate inhibitor of CYP3A4, on the pharmacokinetics of tamsulosin in different CYP2D6 genotypesJi-Yeong Byeon, Yun Jeong Lee, Young-Hoon Kim, et al.
Archives of Pharmacal Research|June 28, 2022
Physiologically based pharmacokinetic modelling to predict the pharmacokinetics of metoprolol in different CYP2D6 genotypesChoong-Min Lee, Pureum Kang, Chang-Keun Cho, et al.
Archives of Pharmacal Research|February 26, 2015
Effects of CYP2C9*1/*3 genotype on the pharmacokinetics of flurbiprofen in Korean subjectsYun-Jeong Lee, Ji-Yeong Byeon, Young-Hoon Kim, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|September 30, 2014
Simultaneous determination of flurbiprofen and its hydroxy metabolite in human plasma by liquid chromatography-tandem mass spectrometry for clinical applicationHye-In Lee, Chang-Ik Choi, Ji-Yeong Byeon, et al.
Pageof 7